“…Conventional chemotherapy has limited benefit in ATL patients given that HTLV-1 cells carry an intrinsic resistance to chemotherapy due to frequent overexpression of the multidrug resistance protein (Lau et al, 1998) and the lung resistance protein (Ikeda et al, 1999). In addition, the constitutive activation of NF-kB, the inhibition of p53 function and the downregulation of Fas-ligand expression in HTLV-I-positive cells (Tamiya et al, 1998) likely protect these cells from chemotherapy-induced apoptosis.…”